Petmed Express Inc

Petmed Express Inc (PETS) Stock Analysis

$1.180

-0.039 (-3.28%)At close

Loading chart…
High
1.215
Open
1.210
VWAP
1.18
Volume
188.44K
Mkt Cap
86.14M
Low
1.150
Amount
222.67K
EV/EBITDA, TTM
-0.99

PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.

AI analysis of Petmed Express Inc (PETS)

Sell

Petmed Express Inc (PETS) is not a good buy right now due to its significantly low current price of $1.18, a very low RSI of 15.415 indicating oversold conditions, and a troubling forward P/E ratio of 16.6945 suggesting overvaluation relative to its earnings outlook. The stock has also seen a drastic year-to-date change of -64.24%, reflecting ongoing financial struggles and negative sentiment. The main risk is its declining revenue trend, with Q3 2026 revenue dropping to $40.66 million from $51.96 million in Q3 2025, indicating a concerning downward trajectory.

Analyst Ratings (5)

Buy
2 Buy
2 Hold
1 Sell
Current: 1.18
Low
—
Average
—
High
—

Morgan Stanley

2026-09-25

Price Target

—

Underweight

Morgan Stanley

2025-04-17

Price Target

$3.2

Sell

Lake Street

2024-08-07

Price Target

$3.5

Hold

Morgan Stanley

2024-06-12

Price Target

$3.5

Sell

Lake Street

2024-06-12

Price Target

$7

Strong Buy

Valuation Metrics

The current forward P/E ratio for Petmed Express Inc (PETS) is 16.69, compared to its 5-year average forward P/E of -10.12.

Forward P/E

Fair
5Y Average P/E
-10.12
Current P/E
16.69
Overvalued
97.17
Undervalued
-117.41

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
7.84
Current EV/EBITDA
-0.99
Overvalued
14.53
Undervalued
1.14

Forward P/S

Fair
5Y Average P/S
0.77
Current P/S
0.17
Overvalued
1.36
Undervalued
0.17

Alphio AI Price Scenarios for PETS

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%PETS

$4.12

Scenario price

B

Base

Base · 50%PETS

$3.76

Scenario price

B

Bear

Bear · 25%PETS

$3.08

Scenario price

Whales holding PETS

O

Oaktop Capital Management II, L.P.

+ HoldingPETS

-9.76%

3M Return

Events Timeline

2026-09-21 (ET)

09:00:00

PetMed Express Appoints Tamar Elkeles as Independent Director

2026-09-17 (ET)

09:00:00

PetMed Express Appoints Jeff Willard as CEO

2026-09-14 (ET)

16:30:00

PetMed Express Appoints Andrew Parry as CTO

2026-07-23 (ET)

08:30:00

PetMed Express Enters $37M Sale-Leaseback Agreement with Investor

2026-06-30 (ET)

10:00:00

PetMed Express Receives $3.00 Acquisition Proposal from SilverCape

News

PETS FAQ — answered by Alphio AI

PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. It operates in the Consumer Non-Cyclicals sector (RETAIL-DRUG STORES AND PROPRIETARY STORES industry).

Petmed Express Inc (PETS) is not a good buy right now due to its significantly low current price of $1.18, a very low RSI of 15.415 indicating oversold conditions, and a troubling forward P/E ratio of 16.6945 suggesting overvaluation relative to its earnings outlook. The stock has also seen a drastic year-to-date change of -64.24%, reflecting ongoing financial struggles and negative sentiment. The main risk is its declining revenue trend, with Q3 2026 revenue dropping to $40.66 million from $51.96 million in Q3 2025, indicating a concerning downward trajectory.

5 analysts cover PETS: 2 rate it Buy, 2 Hold and 1 Sell.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading